We contoured the treated lobe and untreated adjacent lobe(s) on CT before and after SABR and calculated their volume changes relative to the contoured total (bilateral) lung volume (TLV). To develop an intratumor partitioning framework for identifying high-risk subregions from (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) and computed tomography (CT) imaging and to test whether tumor burden associated with the high-risk subregions is prognostic of outcomes in lung cancer.In this institutional review board-approved retrospective study, we analyzed the pretreatment FDG-PET and CT scans of 44 lung cancer patients treated with radiation therapy. These could improve identification of patients at risk for cancer progression and selection of therapy.We performed deep sequencing (CAPP-Seq) analyses of plasma cell-free DNA collected from 45 patients before and after chemoradiotherapy for esophageal cancer, as well as DNA from leukocytes, and fixed esophageal tumor biopsies collected during esophagogastroduodenoscopy. Applying EPIC-seq to serial blood samples from patients treated with PD-(L)1 immune-checkpoint inhibitors, we show that gene expression profiles inferred by EPIC-seq are correlated with clinical response. View details for DOI 10.1038/s41587-021-00981-w, View details for DOI 10.1016/j.jtho.2021.06.017, View details for Web of Science ID 000680263503187, View details for DOI 10.1200/JCO.2021.39.15_suppl.7565, View details for Web of Science ID 000708120604161, View details for DOI 10.1200/JCO.2021.39.15_suppl.8533, View details for Web of Science ID 000708120604247, View details for Web of Science ID 000641160600094, View details for Web of Science ID 000641160600097, View details for Web of Science ID 000641160600087. The clinical utility of circulating tumor DNA (ctDNA) monitoring has been shown in tumors that harbor highly recurrent mutations. No statistically significant gene expression signature was identified for CD4+ cells. The role of trimodality therapy for locally advanced non-small cell lung cancer (NSCLC) continues to be defined. Of the metastases treated, 129 (50%) were brain, 50 (20%) liver, 49 (19%) spine, and 28 (11%) lung. Our findings challenge the prevailing paradigm that local ablative radiotherapy beneficially stimulates the immune response. No additional markers were lost on longer-term follow-up. INTRODUCTION/BACKGROUND: Differentiating local recurrence (LR) from post-treatment changes following stereotactic ablative radiotherapy (SABR) for thoracic tumors is challenging. This emphasizes the need for gating techniques with beam-on/-off controlled directly by the actual position of the tumor target instead of external surrogates such as RPM. We correlated lobar volume reduction with the volume receiving high biologically effective doses (BED, α/β = 3).27 patients met the inclusion criteria, with a median CT follow-up time of 14 months. Although previous studies have suggested that treating multiple lung tumors with SABR is safe, post-treatment changes in respiratory function have not been analyzed in detail.We retrospectively identified patients with 2 or more primary lung cancers or lung metastases treated with SABR and analyzed clinical outcomes and predictors of toxicity. Highly aneuploid non-small cell lung cancer shows enhanced responsiveness to concurrent radiation and immune checkpoint blockade. Predefined secondary outcomes were toxic effects of SABR, local control at 6 months with SABR, progression-free survival, Brief Pain Inventory (Short Form)-measured quality of life, and concordance between conventional imaging and prostate-specific membrane antigen (PSMA)-targeted positron emission tomography in the identification of metastatic disease.In the 54 men randomized, the median (range) age was 68 (61-70) years for patients allocated to SABR and 68 (64-76) years for those allocated to observation. Preclinical studies indicate that radiotherapy synergizes with immunotherapy, promoting radiation-induced antitumor immunity. The approach and analytical pipelines generated in this work, as well as the specificity groups defined here, present a resource for understanding the T cell response in cancer. Covariates associated with decreased OS included male sex (HR 4.5, P < 0.05), age over 65 (HR 1.77, P < 0.05), ECOG status 2 or greater (HR 1.94, P < 0.05), SCC histology (HR 1.66, P < 0.05), and T stage 2 disease (HR 1.68, P < 0.05).CONCLUSION: In this observational cohort of patients treated at VHAMCs, facility TV was not associated with survival outcomes for early-stage NSCLC radiation treatment using SABR technique. View details for DOI 10.1016/j.ijrobp.2013.08.015. (973) 449-3214. Giving lapatinib
The U-Net algorithm has not seen any other clinical information (e.g. Prognostic factors for false-positive FDG-PET-CT were assessed using logistic regression models.RESULTS: We identified 145 patients meeting inclusion criteria for the retrospective analysis. Here we perform a comprehensive molecular analysis of a randomized phase I clinical trial of patients with non-small cell lung cancer (NSCLC) treated with concurrent or sequential ablative radiotherapy and ICB. This webinar aims to review and discuss data for liquid biopsy-based assessments as endpoints of antitumour activity in clinical trials, understand the potential and limitations of liquid biopsy-based tumour genomic profiling for patient stratification and detection of predictive biomarkers of response to therapy, and . Li, R., Han, B., Meng, B., Maxim, P., Diehn, M., Xing, L., Koong, A., Loo, B. Patients treated with radiation therapy for lung tumors can experience inflammation after
Purpose Clinical use of analytical tests to assess genomic variants in circulating tumor DNA (ctDNA) is increasing. View details for DOI 10.1016/j.semradonc.2015.05.001, View details for PubMedCentralID PMC4575502. measure tumor hypoxia. Maximilian Diehn, Mary Hawn, Michelle Monje, and Carla Pugh. A., Chabon, J. J., Lovejoy, A. F., Newman, A., Stehr, H., Azad, T. D., Carter, J. N., Merriott, D. J., Liu, C. L., Kurtz, D. M., Gensheimer, M. F., Shrager, J. The 4D-CT VAS was 0.0±2.7.This study demonstrated a high patient dependence on the use of AV biofeedback to reduce motion artifacts in 4D imaging. The explosion in the number of functional genomic datasets generated with tools such as DNA microarrays has created a critical need for resources that facilitate the interpretation of large-scale biological data. View details for DOI 10.3390/cancers14102479. Patterns of Care in Patients With Isolated Nodal Recurrence After Definitive Stereotactic Ablative Radiotherapy for Non-Small Cell Lung Cancer. View details for DOI 10.1186/1471-2164-5-64, View details for Web of Science ID 000224203400001, View details for PubMedCentralID PMC521069, View details for Web of Science ID 000223338000683. cancer patients and in patients suspected of having cancer. At the beginning of each fraction, individualized respiratory gating amplitude thresholds were set based on fluoroscopic image guidance. ctDNA remained undetectable in patients without recurrence, or low-level in a patient receiving maintenance erlotinib. These studies suggest that there is a cancer stem cell compartment in the MMTV-Wnt-1 murine breast tumor and that there is a clinical utility of this model for the study of cancer stem cells. Monday - Friday, 8 a.m. - 5 p.m. Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma. MPNs were also manually delineated on deep inhale and exhale images by two observers. To evaluate the prognostic value and molecular basis of a CT-derived pleural contact index (PCI) in early stage non-small cell lung cancer (NSCLC).We retrospectively analysed seven NSCLC cohorts. At the 2014 Next Generation Dx Summit, Harvard University's Sunney Xie and Stanford University's Maximilian Diehn provided insight into novel next-generation. Chabon, J. J., Hamilton, E. G., Kurtz, D. M., Esfahani, M. S., Moding, E. J., Stehr, H., Schroers-Martin, J., Nabet, B. Y., Chen, B., Chaudhuri, A. Kurtz, D., Chabon, J. J., Soo, J., Keh, L., Alig, S., Schultz, A., Jin, M. C., Scherer, F., Craig, A. M., Liu, C., Duehrsen, U., Huettmann, A., Casasnovas, R., Westin, J., Roschewski, M. J., Wilson, W., Gaidano, G., Rossi, D., Diehn, M., Alizadeh, A. Terezakis, S. A., Heron, D. E., Lavigne, R. F., Diehn, M., Loo, B. W. HIGH RETENTION AND SAFETY OF PERCUTANEOUSLY IMPLANTED ENDOVASCULAR EMBOLIZATION COILS AS FIDUCIAL MARKERS FOR IMAGE-GUIDED STEREOTACTIC ABLATIVE RADIOTHERAPY OF PULMONARY TUMORS. The systemic activation of antitumor macrophages following radiotherapy and CD47 blockade may be particularly important in patients with cancer who suffer from metastatic disease. This procedure (lobectomy) does not fulfill the medical need as many
The effect of arm position on the dosimetry of thoracic stereotactic ablative radiation therapy using volumetric modulated arc therapy. GFPT2-Expressing Cancer-Associated Fibroblasts Mediate Metabolic Reprogramming in Human Lung Adenocarcinoma, Combination Approach for Detecting Different Types of Alterations in Circulating Tumor DNA in Leiomyosarcoma, Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma, Case series of MET exon 14 skipping mutation-positive non-small-cell lung cancers with response to crizotinib and cabozantinib, Invasive nodal evaluation prior to stereotactic ablative radiation for non-small cell lung cancer, SABR-COMET: harbinger of a new cancer treatment paradigm, The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy, A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer, F-18-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated With Highly Conformal Radiation Therapy, Prognostic Value of Pretreatment FDG-PET Parameters in High-dose Image-guided Radiotherapy for Oligometastatic Non-Small-cell Lung Cancer, Line-Enhanced Deformable Registration of Pulmonary Computed Tomography Images Before and After Radiation Therapy With Radiation-Induced Fibrosis, A Feasibility Study of Single-inhalation, Single-energy Xenon-enhanced CT for High-resolution Imaging of Regional Lung Ventilation in Humans, Clinical impact of dose overestimation by effective path length calculation in stereotactic ablative radiation therapy of lung tumors. A. Kurtz, D. M., Scherer, F., Jin, M. C., Soo, J., Craig, A. F., Esfahani, M. S., Chabon, J. J., Stehr, H., Liu, C. L., Tibshirani, R., Maeda, L. S., Gupta, N. K., Khodadoust, M. S., Advani, R. H., Newman, A. M., Duhrsen, U., Huttmann, A., Meignan, M., Casasnovas, O., Westin, J. R., Roschewski, M., Wilson, W. H., Gaidano, G., Rossi, D., Diehn, M., Alizadeh, A. No grade 3-5 toxicity was observed. In this review, we present an overview of techniques used for noninvasive molecular disease detection in selected myeloid and lymphoid neoplasms, with a focus on the current and future role of HTS-based assays. Most relapsed/refractory large B cell lymphoma (r/rLBCL) patients receiving anti-CD19 chimeric antigen receptor (CAR19) T cells relapse. This study demonstrates that transformation from FL to DLBCL can occur by alternative pathways and that transformed DLBCL and de novo DLBCL have very different gene-expression profiles that may underlie the different clinical behaviors of these two types of morphologically similar lymphomas. The use of texture-based radiomics CT analysis to predict outcomes in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapy. A research study of a procedure to treating lung cancer with focused radiation called
Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy Recruiting. Luca, B. View details for DOI 10.1109/TMI.2016.2591921, View details for Web of Science ID 000391547700011, View details for PubMedCentralID PMC5114547. There were six dose/fractionation schedules used, depending on gross tumor volume (≤10cc, 10-30cc, > 30cc) and location (peripheral vs. central). We assessed the association of these metrics and their changes from before to mid-RT using positron emission tomography-computed tomography (PET-CT) with OS and PFS.We identified 29 patients, all with pre-RT and 20 with mid-RT PET-CT scans. Human oesophageal stem cell research is hampered by the lack of an optimal assay system to study self-renewal and differentiation. CT Perfusion Imaging in Predicting Treatment Response in Patients With Non-small Cell Lung Cancer or Lung Metastases Treated With Stereotactic Ablative Radiation Therapy. Quantitative PET imaging characteristics including statistical, histogram-related, morphologic, and texture features were analyzed, from which 35 nonredundant and robust features were further evaluated. Patients with Stage III unresectable non-small cell lung cancer will receive thoracic
This test set consisted of 50 primary lung cancers and 9 metastases. Notably, SLP-76 contains a predicted binding motif for the Itk SH2 domain and binds to full-length Itk in vitro. View details for PubMedCentralID PMC4109543. If validated, ctDNA surveillance may facilitate personalization of the duration of immune checkpoint blockade and enable early intervention in patients at high risk for progression. Because cancer is caused by an accumulation of genetic mutations, mutant DNA released by tumors can be used as a highly specific biomarker for cancer. therapy or conventionally fractionated radiation therapy with durvalumab will work better in
The most prominent feature of the cell type signature genes was the enrichment of genes encoding cell surface proteins, perhaps reflecting the importance of specialized systems for sensing the environment to the physiology of resting leukocytes. Stanford is currently not accepting patients for this trial. We anticipate that iDES will aid the noninvasive genotyping and detection of ctDNA in research and clinical settings. View details for DOI 10.1073/pnas.0402870102, View details for Web of Science ID 000228565200034, View details for PubMedCentralID PMC556127. markers may be useful for confirming the diagnosis or for selecting patients for specific
year. (INT J RADIATION ONCOL BIOL PHYS 2011;78:1600) REPLY, Mechanisms of Radioresistance in Cancer Stem Cells, INFLUENCE OF TUMOR HYPOXIA ON STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR): RESPONSE TO DRS. 54 men with oligometastatic prostate adenocarcinoma will be accrued. Radiation therapy uses high energy x rays to kill tumor cells. B., Ishisoko, N. n., Kildebeck, E. n., Newman, A. M., Bratman, S. V., Porteus, M. H., Chang, H. Y., Alizadeh, A. chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. This approach achieves performance similar to that of tumour-informed ctDNA detection and enables tuning of assay specificity in order to facilitate distinct clinical applications. The most exciting clinical implication of the current findings is the potential to therapeutically target CD26 for the treatment and/or prevention of metastatic colorectal cancer. The availability of blood-based tests could increase screening uptake. B., Hayes, D. N., Diehn, M., Le, Q. T. STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. View details for Web of Science ID 000444944200019, View details for DOI 10.1016/j.cllc.2018.04.003, View details for Web of Science ID 000442538700007. B., Arbour, K. C., Luo, J. n., Preeshagul, I. R., Moding, E. J., Almanza, D. n., Bonilla, R. F., Sauter, J. L., Choi, H. n., Tenet, M. n., Abu-Akeel, M. n., Plodkowski, A. J., Perez-Johnston, R. n., Yoo, C. H., Ko, R. B., Stehr, H. n., Gojenola, L. n., Wakelee, H. A., Padda, S. K., Neal, J. W., Chaft, J. E., Kris, M. G., Rudin, C. M., Merghoub, T. n., Li, B. T., Alizadeh, A. A., Loo, B. W., Diehn, M. Genetic determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response In Vivo. Capaldi, D. P., Binkley, M. S., Ko, R., Xing, L., Maxim, P. G., Diehn, M., Loo, B. W. A noninvasive approach for early prediction of therapeutic benefit from immune checkpoint inhibition for lung cancer. Kuo, P., Bratman, S. V., Shultz, D. B., von Eyben, R., Chan, C., Wang, Z., Say, C., Gupta, A., Loo, B. W., Giaccia, A. J., Koong, A. C., Diehn, M., Quynh-Thu Le, Q. T. Pulmonary Ventilation Imaging Based on 4-Dimensional Computed Tomography: Comparison With Pulmonary Function Tests and SPECT Ventilation Images. Molecular disease measured from plasma, compared with circulating leukocytes, was more abundant and better correlated with radiographic disease burden. Marar, M., Bryant, A. K., Nalawade, V., Das, M., Jr, B. W., Diehn, M., Chin, A. L., Murphy, J. D., Vitzthum, L. Impact of Facility Treatment Volume on Stereotactic Ablative Radiotherapy (SABR) Outcomes in Early-Stage Non-Small Cell Lung Cancer (NSCLC). Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non-Small-Cell Lung Cancer in the United States and Vietnam. Our approach may be clinically useful not only in LMS but also in other tumor types that lack recurrent genomic alterations. Quantitation of ctDNA could allow objective response assessment, detection of minimal residual disease and noninvasive tumor genotyping. Tumor size distribution was: ≤10cc, 74%; 10-30cc, 19%; > 30cc, 7%. is a co-founder of Foresight Diagnostics and Associate Professor of Radiation Oncology, Vice Chair of Research. Moding, E. J., Maxim, P. G., Diehn, M., Loo, B. W., Gensheimer, M. F. Outcomes of Moderately Hypofractionated Intensity-Modulated Thoracic Radiotherapy with Concurrent Chemotherapy for Treatment of Non-Small Cell Lung Cancer. Open trials refer to studies currently accepting participants. Detection of ctDNA following chemoradiotherapy was associated with tumor progression (hazard ratio, 18.7; P We identified cases of NSCLC with METex14 mutations using an institutionally developed or commercial next-generation sequencing assay. This study hopes to evaluate the use of breath analysis to evaluate changes in the
Irradiated shGal-1 tumors showed significantly less intratumoral CD8(+) T-cell apoptosis and microvessel density, which led to marked tumor growth delay and reduced lung metastasis compared with controls. This dataset was used to train two 3D U-Net convolutional neural networks with varying model properties: one using high-resolution and small input volumes, and one using low-resolution and large input volumes. Notably, CD47 blockade also stimulates off-target 'abscopal' effects inhibiting non-irradiated SCLC tumors in mice receiving radiation. microarray analyses of host-pathogen interactions, Stereotyped and specific gene expression programs in human innate immune responses to bacteria, In vivo regulation of human skeletal muscle gene expression by thyroid hormone, Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. Jeong, Y., Rhee, H., Martin, S., Klass, D., Lin, Y., Le Xuan Truong Nguyen, L. X., Feng, W., Diehn, M. Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR). Gensheimer, M. F., Hong, J. C., Chang-Halpenny, C. N., Eclov, N., To, J., Murphy, J. D., Wakelee, H. A., Neal, J. W., Le, Q. T., Hara, W., Quon, A., Maxim, P. G., Graves, E. E., Olson, M. R., Diehn, M., Loo, B. W. Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome. Time to toxicity was defined from start of SABR.Of 47 patients with central tumors in the right lung treated with SABR reviewed, 13 met our study criteria. View details for DOI 10.1016/j.ccell.2022.12.005. This resource and associated analytical tools (http://precog.stanford.edu) may help delineate prognostic genes and leukocyte subsets within and across cancers, shed light on the impact of tumor heterogeneity on cancer outcomes, and facilitate the discovery of biomarkers and therapeutic targets. The experimentally determined localizations correlated well with in silico predictions of signal peptides and transmembrane domains, but also significantly increased the number of human genes that could be cataloged as encoding either MS or CN proteins. Yang, J., Yamamoto, T., Gopalan, S., Cui, G., Diehn, M., Berger, J., Loo, B. W., Graves, E. E., Keall, P. J. King, M. T., Maxim, P. G., Diehn, M., Loo, B. W., Xing, L. Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central lung tumors. B., Ross, J. B., Hoang, C. D., Bazan, J., Maxim, P. G., Graves, E. E., Diehn, M., Hara, W. Y., Quon, A., Quynh-Thu Le, Q. T., Wakelee, H. A., Loo, B. W. INFLUENCE OF TUMOR HYPOXIA ON STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR): RESPONSE TO DRS. Ko, R. B., Jani, K., Sodji, Q., Merriott, D. J., Pickthorn, W., Bush, K., Maxim, P. G., Diehn, M., Loo, B. W. Influence of Dose and Fractionation on Radiologic Lung Fibrosis after Stereotactic Ablative Radiotherapy (SABR). Highly conformal radiation therapy was given to treat intrathoracic disease in 15 fractions to a total of 50, 55, or 60 Gy.Fifty-five patients were enrolled: 15 at the 50-Gy, 21 at the 55-Gy, and 19 at the 60-Gy dose levels. Wisdom, A. J., Mowery, Y. M., Hong, C. S., Himes, J. E., Nabet, B. Y., Qin, X. n., Zhang, D. n., Chen, L. n., Fradin, H. n., Patel, R. n., Bassil, A. M., Muise, E. S., King, D. A., Xu, E. S., Carpenter, D. J., Kent, C. L., Smythe, K. S., Williams, N. T., Luo, L. n., Ma, Y. n., Alizadeh, A. The latter property is incorporated both into a kernel for support vector machines (SVM) and a manifold-aware sparse regularized classifier. Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA, Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy, Identification and genetic manipulation of human and mouse oesophageal stem cells, Molecular profiling of single circulating tumor cells from lung cancer patients. Withdrawal from the study prior to 6 months will be counted as progression. This work aims to develop an image-based prognostic signature and assess its complementary value to existing biomarkers.We retrospectively analyzed data of stage I NSCLC in 8 cohorts. Characterizing metastatic cancer stem cells from human breast cancer, Increases in Serial Pretreatment F-18-FDG PET-CT Metrics Predict Survival in Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiation Therapy. Obeid, J. P., Natarajan, J. M., Ko, R., Jani, K., Sodji, Q., Merriott, D. J., Pickthorn, W., Bush, K., Maxim, P. G., Diehn, M., Loo, B. W. Pre-Treatment Lung FDG-PET Uptake is Correlated with Radiologic Lung Fibrosis after Stereotactic Ablative Radiotherapy (SABR). We will review the history of radiation for LA-NSCLC and discuss the role of induction, concurrent and consolidative chemotherapy as well as the concerns for late cardiac and pulmonary toxicities associated with treatment. These results are consistent with mutational frequencies in human EGFR- and KRAS-driven lung adenocarcinomas. We report our institutional experience treating patients with MET exon 14 skipping (METex14) mutations, including responses to the MET inhibitors crizotinib and cabozantinib. Taken together, these results demonstrate that integrated ctDNA and circulating immune cell profiling can provide accurate, noninvasive, and early forecasting of ultimate outcomes for NSCLC patients receiving ICIs. View details for DOI 10.1136/gutjnl-2014-308491, View details for Web of Science ID 000377170200005. Lau, B., No, H., (Fred) Wu, Y., Devine, M., Ko, R., Loo, B., Diehn, M., Chin, A., Vitzthum, L. Treatment Patterns for Isolated Nodal Recurrences in Non-Small Cell Lung Cancer After Definitive Stereotactic Ablative Radiotherapy. He is very focused , extremely RATIONALE: Vaccines may help the body build an effective immune response to kill tumor cells. One to 7 metallic fiducial markers were implanted inside or near the tumor target before treatment simulation. These changes were associated with a CD8(+) T-cell response, which was improved in combination with checkpoint immunotherapy. ctDNA analysis for personalization of consolidation immunotherapy in localized non-small cell lung cancer. Furthermore, the ctDNA response pattern early during CICI identified patients responding to consolidation therapy. However, dissecting these cell states and their clinical relevance at scale remains challenging. These data indicate that modulation of the GDNF pathway may have potential therapeutic benefit for management of radiation-induced xerostomia. According to preclinical studies, this therapy kills cancer cells and immunosuppressive myeloid cells in the tumor microenvironment, leading to T-cell mediated anti-tumor immune activity. By our estimated dose recalculation, the GTV was consistently covered by the prescription dose (PD), that is, V100% above 0.97 for all patients, and minimum dose to GTV >100% PD for 18 patients and >95% PD for all patients.Intrafraction CBCT during VMAT can provide geometric and dosimetric verification of SABR valuable for quality assurance and potentially for treatment adaptation. A., Diehn, M. Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. We found that the gene expression patterns in paired specimens from the same GBM invariably were more closely related to each other than to any other tumor, even when the paired specimens had strikingly divergent histologies.
Graham Coxon Essy Syed,
Bundesliga Vertragsende 2022,
Was Zahlt Der Beihilfeergänzungstarif Debeka,
Marion Ohlsen Katharina Hirtreiter,
Wenn Du Mich Auf Die Seite Legst, Bin Ich Alles,